Compare CRTO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | ORIC |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | France | United States |
| Employees | 3649 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.6M | 837.3M |
| IPO Year | 2013 | 2020 |
| Metric | CRTO | ORIC |
|---|---|---|
| Price | $16.41 | $8.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $34.00 | $19.73 |
| AVG Volume (30 Days) | 235.3K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | 19.67 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | $5.92 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $4.65 |
| 52 Week High | $28.91 | $14.93 |
| Indicator | CRTO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 35.69 |
| Support Level | N/A | $7.90 |
| Resistance Level | $20.10 | $12.40 |
| Average True Range (ATR) | 0.90 | 0.56 |
| MACD | -0.31 | -0.08 |
| Stochastic Oscillator | 18.63 | 3.09 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.